The 2026 position is more compliance-led, more international and more dependent on cost mapping. The most important shift is that tax authorities increasingly expect claims to show who benefited from the R&D, where the work was done, how costs were allocated and how grants interacted with the tax position.
For CFOs and Heads of Tax, the main 2026 planning points are:
Headline rates are useful for screening, but they do not show the real cash outcome. Finance leaders should use comparison tables to identify opportunities, then run a country-specific assessment of caps, refundability, grants, contract R&D, IP ownership and audit burden.
Country |
Main R&D tax mechanism |
2026 headline position |
CFO watchpoint |
| United Kingdom | Merged R&D Expenditure Credit and ERIS | 20% above-the-line credit under the merged scheme, with enhanced support for qualifying loss-making R&D-intensive SMEs | Overseas costs, subcontracting, AIF evidence and HMRC enquiry readiness |
| Germany | Forschungszulage tax allowance | 25% general rate, 35% for qualifying SMEs, subject to local caps and rules | BSFZ certification, eligible base, 70% contract R&D treatment and refund mechanics |
| Spain | R&D and innovation tax credits | 25% volume credit, with higher incremental support available in some cases | Binding reports, monetisation conditions and regional interaction |
| Singapore | Enterprise Innovation Scheme and negotiated incentives | Enhanced deductions can create a high tax value on qualifying spend | Local beneficiary, IP position and substance in Singapore |
| United States | Federal research credit, plus state incentives | Federal credit mechanics vary by calculation method, with state-level add-ons | Section 41 qualification, documentation and interaction with domestic R&E deduction rules |
| Belgium | Payroll withholding relief, investment deductions, Innovation Income Deduction | Broad toolbox covering staff costs, capex and IP income | Qualification of R&D staff, BELSPO process and IP income tracking |
| France | CIR, CII and related regimes | CIR remains a major 30% regime up to the main threshold, with reduced rates above it | Subcontractor accreditation, finance act changes and technical file quality |
| Canada | SR&ED | Refundable and non-refundable investment tax credits, depending on company type and expenditure | 18-month filing deadline, provincial rules and CRA review file |
| Chile | CORFO-certified R&D tax credit | 35% credit on certified R&D, with remaining costs generally deductible | Ex-ante certification and local activity requirements |
| Uruguay | R&D and innovation credits | 35% to 45% credit, with higher support for certain collaborations | University or technology centre collaboration and local approval requirements |
This expert-led guide delivers:
A full breakdown of R&D tax schemes across more than 20 jurisdictions
Clear, comparative tables of available benefits
Eligibility criteria for activities, expenditure, and legal structure
Claim procedures, submission windows, and compliance tips
Country-by-country insights into grant compatibility and IP treatment
It’s the definitive reference for CFOs, tax leads, and innovation officers managing global R&D portfolios.
This expert-led guide delivers:
A full breakdown of R&D tax schemes across more than 20 jurisdictions
Clear, comparative tables of available benefits
Eligibility criteria for activities, expenditure, and legal structure
Claim procedures, submission windows, and compliance tips
Country-by-country insights into grant compatibility and IP treatment
It’s the definitive reference for CFOs, tax leads, and innovation officers managing global R&D portfolios.
Higher GERD/GDP usually correlates with mature R&D tax schemes and tighter compliance. Illustrative 2025 guide figures show USA 3.5%, Belgium 3.22%, Germany 3.13%, United Kingdom 2.77%, Netherlands 2.296%, France 2.18%, Singapore 2.2%, Portugal 1.56%, Canada 1.7%, Spain 1.41%, Brazil 1.2%, Uruguay 0.6%, Chile 0.39%.
This chart shows how much of each country’s GDP is invested in R&D. The USA, Belgium and Germany lead at over 3% of GDP, while the UK, France, Netherlands and Singapore sit around the 2% range. Emerging markets like Brazil, Uruguay and Chile invest less than 1%, but still offer attractive local tax schemes.
This chart compares the headline benefits of major R&D tax schemes. Rates vary: Singapore’s EIS delivers the highest after-tax benefit (68%), Germany offers up to 35% for SMEs, the UK’s merged credit gives around 20%, Spain provides 25% volume relief, and the US credit averages 13%. Each scheme has unique eligibility, refundability and compliance rules.
CFOs should hold evidence that proves the R&D activity, links costs to that activity and explains why the claimant entity is entitled to the benefit. This matters more in 2026 because many authorities now test claims against project records, contracts, payroll data and IP arrangements.
International R&D tax evidence checklist
Before filing, build an evidence file covering:
For software groups, this is especially important. Agile delivery can create strong evidence, but only if sprint records, architecture decisions, testing logs and unresolved technological uncertainty are translated into a tax authority-ready narrative.
“Plan the beneficiary position, the IP route to exploitation and the subcontracting chain before the first sprint. Software needs the same rigour as hardware, so show the uncertainty, the hypotheses, the tests and the iteration, and link every cost line to that story. If you can hand an inspector that narrative in ten minutes, you are already ahead.” – Gabriel Aduculesei, R&D Tax Lead, Software & IT, FI Group by EPSA
The FI Group’s International Grants Guide 2025 is a comprehensive reference for businesses and institutions looking to leverage public funding opportunities worldwide. Covering over a dozen countries, the guide breaks down national and regional schemes that support R&D, innovation, energy efficiency, sustainability, and industrial transformation.
The FI Group’s International Grants Guide 2025 is a comprehensive reference for businesses and institutions looking to leverage public funding opportunities worldwide. Covering over a dozen countries, the guide breaks down national and regional schemes that support R&D, innovation, energy efficiency, sustainability, and industrial transformation.
Finance leaders should compare international R&D locations using a weighted funding model, not a simple rate table. The right model combines tax value, grant availability, audit burden, operational substance, hiring plans, IP strategy and long-term commercial use.
Comparison framework
| Factor | Question |
| Net incentive value | What is the likely after-tax and after-grant benefit? |
| Cash timing | Is the incentive refundable, payable, carried forward or offset only? |
| Evidence burden | What documentation will the local authority expect? |
| Cost eligibility | Are staff, contractors, cloud, software, depreciation and overseas costs eligible? |
| IP ownership | Does the claimant own or control the resulting intellectual property? |
| Group structure | Do transfer pricing and intercompany contracts support the claim? |
| Grant compatibility | Can national, regional or EU grants be combined safely? |
| Audit exposure | What is the likely enquiry risk and time cost if challenged? |
| Operational reality | Does the company have real people, activity and decision-making in that country? |
This matters for board reporting. A project may look attractive in a high-rate country but become weaker once the team location, IP route, grant restrictions and tax capacity are considered.
FI Group by EPSA helps businesses align global R&D tax, grants and innovation funding into one coordinated strategy. The goal is to give HQ a clear funding view while local experts manage country-specific rules, language, filings and evidence expectations.
For CFOs, this means:
Global Reach. Local Expertise. Your HQ sees the full picture. Your local teams get the support they need to file properly.
International R&D tax schemes in 2026 remain highly valuable, but the headline rate is only the starting point. CFOs need to compare the after-tax, after-grant and after-risk outcome across jurisdictions, then align project location, IP ownership, subcontracting, grant funding and evidence before major R&D spend is committed.
For UK groups operating internationally, the key question to ask is: where can our business generate a defensible, compliant and forecastable cash outcome without creating audit, transfer pricing or grant clawback issues later?
The leading 2025 international R&D tax schemes mix tax credits, super-deductions, reduced social contributions and IP/patent boxes. Headlines include the UK’s merged 20% credit, Germany’s 35% SME credit, Spain’s 25% volume plus 42% incremental, Singapore’s 68% after-tax benefit on the first S$400k, and US credits up to 13%, each with specific eligibility and interaction rules.
Most regimes share the same commercial aim: to encourage businesses to invest more in innovation. The practical rules vary widely. CFOs should compare: